Pharmacist Perspectives on Novel Agents in Multiple Myeloma

Learning Objectives

MM Therapy Progression

Recently Approved Agents

Patient Case 1

Ixazomib

Ixazomib Drug Interactions

TOURMALINE-MM1 Ixazomib + Len/Dex vs Placebo + Len/Dex

TOURMALINE-MM1 Toxicity

Ixazomib Practical Points

Patient Case 2

Monoclonal Antibodies

ELOQUENT-2 Elotuzumab + Len/Dex vs Len/Dex

ELOQUENT-2 Toxicity

Elotuzumab Practical Points

Patient Case 3

Daratumumab

Daratumumab Monotherapy Phase 2 Study, ≥ 3 Lines of Prior Therapy

Daratumumab Additional Points

Daratumumab Combination Treatment CASTOR and POLLUX

CASTOR and POLLUX Efficacy

CASTOR and POLLUX Toxicity

CASTOR and POLLUX IRRs

Future Directions

Select Therapies in Development

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)